PAVmed Inc.

PAVmed Inc.

NNASDAQ:PAVM
1.75
USD
+0.12
(+7.36%)
-6.92EPS
43.20MMarket Cap
Mar 30Next Earn

Total Valuation

USD

As of June 30, 2026, PAVmed Inc. carries a market capitalization of 43.20M, placing it among publicly traded companies globally. Its enterprise value stands at 44.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap43.20M
Enterprise Value44.59M

Important Dates

PAVmed Inc.'s next confirmed earnings release is scheduled for March 30, 2027.

Earnings Date3/30/2027

Share Statistics

As of June 30, 2026, PAVmed Inc. has 7.27M shares outstanding.

Shares Outstanding7.27M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 125.91, and the price-to-book ratio stands at 1.38.

PS Ratio125.91
PB Ratio1.38
P/TBV Ratio1.38
P/FCF Ratio-1.81
P/OCF Ratio-1.82

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 398.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 44.59M versus a market cap of 43.20M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales398.15

Financial Position

As of June 30, 2026, PAVmed Inc. maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 88.40, indicating elevated leverage, while an interest coverage ratio of -1,479.17 demonstrates limited ability to service its debt obligations.

Current Ratio1.19
Quick Ratio0.93
Debt / Equity88.40
Debt / EBITDA-0.64
Interest Coverage-1,479.17

Financial Efficiency

USD

Over the twelve months ended June 30, 2026, PAVmed Inc. posted a negative return on equity (ROE) of -93.42, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -28.75, reflecting losses generated across the asset base. The company generates approximately 2,765.43 in revenue per employee across its workforce of 40.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.52 indicates how many times PAVmed Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-93.42
Return on Assets (ROA)-28.75
Revenue Per Employee2,765.43
Employee Count40.50
Inventory Turnover1.52

Stock Price Statistics

USD

As of the close on November 16, 2026, PAVmed Inc.'s stock has declined approximately 81.77% over the past 52 weeks. The 50-day moving average sits at 2.80, while the 200-day moving average is 6.18.

52-Week Price Change-81.77%
50-Day Moving Average2.80
200-Day Moving Average6.18

Income Statement

USD

Over the twelve months ended June 30, 2026, PAVmed Inc. generated 112,000.00 in revenue and converted that into -12.09M in net income, yielding earnings per share of -6.92. EBITDA reached -26.62M, while operating income came in at -25.91M.

Revenue112,000.00
Gross Profit-247,000.00
Operating Income-25.91M
Pretax Income-16.43M
Net Income-12.09M
EBITDA-26.62M
EBIT-26.70M
Earnings Per Share (EPS)-6.92

Balance Sheet

USD

As of June 30, 2026, PAVmed Inc. holds 3.78M in cash and equivalents against 17.07M in total debt, resulting in a net debt position of 11.32M. Total book value stands at 31.20M, with working capital of 770,000.00 providing operational flexibility.

Cash & Cash Equivalents3.78M
Total Debt17.07M
Net Debt11.32M
Equity (Book Value)31.20M
Book Value Per Share4.29
Working Capital770,000.00

Cash Flow

USD

PAVmed Inc. produced -7.73M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -52,000.00 in capital expenditures, free cash flow totaled -7.78M - equivalent to -3.28 per share.

Operating Cash Flow-7.73M
Capital Expenditures-52,000.00
Free Cash Flow-7.78M
FCF Per Share-3.28

Margins

Over the twelve months ended June 30, 2026, PAVmed Inc. posted a gross margin of -220.54, reflecting its pricing power and cost economics. The operating margin of -23,131.25 and net profit margin of -10,794.64 provide insight into operational efficiency.

Gross Margin-220.54
Operating Margin-23,131.25
Pretax Margin-14,669.64
Profit Margin-10,794.64
EBITDA Margin-23,772.32

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of 29.13 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -55.18: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -17.50, meaning PAVmed Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Payout Ratio29.13
Shareholder Yield-17.50
FCF Yield-55.18

Stock Splits

PAVmed Inc.'s most recent stock split took place on January 2, 2026 with a 30:1 split ratio.

Last Split Date1/2/2026
Split Ratio30:1

Scores

As of June 30, 2026, PAVmed Inc. has an Altman Z-Score of -10.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-10.07